Background: The prevalence of schizophrenia and depression in the United States is far higher among Medicaid recipients than in the general population. Individuals suffering from mental illness, including schizophrenia and depression, also have higher rates of emergency department utilization, which is costly and may not generate the positive health outcomes desired. Disease management programs strive to help individuals suffering from chronic illnesses better manage their condition(s) and seek health care in the appropriate settings. The objective of this manuscript is to estimate a dose-response impact on hospital inpatient and emergency room utilizations for any reason by Medicaid recipients with depression or schizophrenia who received disease management contacts.

Methods: Multivariate regression analysis of panel data taken from administrative claims was conducted to test the hypothesis that increased contacts lower the likelihood of all-cause inpatient admissions and emergency room visits. Subjects included 6,274 members of Illinois' non-institutionalized Medicaid-only aged, blind or disabled population diagnosed with depression or schizophrenia. The statistical measure is the odds ratio. The odds ratio association is between the monthly utilization indicators and the number of contacts (doses) a member had for each particular disease management intervention.

Results: Higher numbers of intervention contacts for Medicaid recipients diagnosed with depression or schizophrenia were associated with statistically significant reductions in all-cause inpatient admissions and emergency room utilizations.

Conclusions: There is a high correlation between depression and schizophrenia disease management contacts and lowered all-cause hospital inpatient and emergency room utilizations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086989PMC
http://dx.doi.org/10.1186/1472-6963-14-288DOI Listing

Publication Analysis

Top Keywords

depression schizophrenia
20
disease management
16
emergency room
16
medicaid recipients
12
multivariate regression
8
regression analysis
8
schizophrenia depression
8
individuals suffering
8
hospital inpatient
8
inpatient emergency
8

Similar Publications

Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia: A Randomized Controlled Trial.

J Clin Psychiatry

January 2025

Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, and Department of Psychiatry, New York University School of Medicine, New York, New York.

There are few established treatments for negative symptoms in schizophrenia, which persist in many patients after positive symptoms are reduced. Oxidative stress, inflammation, and epigenetic modifications involving histone deacetylase (HDAC) have been implicated in the pathophysiology of schizophrenia. Sulforaphane has antioxidant properties and is an HDAC inhibitor.

View Article and Find Full Text PDF

Objective: The aim of the study was to investigate the therapeutic effects of modified electroconvulsive therapy (MECT) in combination with risperidone tablets and psychotherapy in the treatment of patients with treatment-resistant schizophrenia (TRS).

Methods: Patients with TRS admitted to the psychiatric department of our hospital between January 2018 and December 2019 were selected as study participants. They were randomly divided into a control group and a study group, with the control group receiving risperidone tablets and psychotherapy, and the study group undergoing MECT as well as the control group treatment.

View Article and Find Full Text PDF

Investigating the Shared Genetic Architecture Between Psychiatric Disorders and Executive Function.

Biol Psychiatry Glob Open Sci

November 2024

Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

Background: Evidence for widespread comorbidity of executive dysfunctions with psychiatric disorders suggests common mechanisms underlying their pathophysiology. However, the shared genetic architectures between psychiatric disorders and executive function (EF) remain poorly understood.

Methods: Leveraging large genome-wide association study datasets of European ancestry on bipolar disorder ( = 353,899), major depressive disorder ( = 674,452), and schizophrenia ( = 130,644) from the Psychiatric Genomics Consortium and iPSYCH and a common factor of EF ( = 427,037) from UK Biobank, we systematically investigated the shared genomic architectures between psychiatric disorders and EF with a set of statistical genetic, functional genomic, and gene-level analyses.

View Article and Find Full Text PDF

The predictive coding framework postulates that the human brain continuously generates predictions about the environment, maximizing successes and minimizing failures based on prior experiences and beliefs. This PRISMA-compliant systematic review aims to comprehensively and transdiagnostically examine the differences in predictive coding between individuals with neuropsychiatric disorders and healthy controls. We included 72 case-control studies investigating predictive coding as the primary outcome and reporting behavioral, neuroimaging, or electrophysiological findings.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!